Ki67/MKI67 Antibody - BSA Free

Ki67 is a nuclear protein associated with proliferation, named after its discovery in a Hodgkin's lymphoma-derived cell line by Scholzer and Gerdes at Kiel University, Germany (1). This proliferation marker is expressed during active phases of the cell cycle (late G1, S, G2 and M), whereas the protein remains undetectable in the G0 phase. Ki67 has two main isoforms with theoretical molecular weights of 319 kDa and 359 kDa. Its abundance is tightly regulated by synthesis and degradation with an estimated half-life of 60-90 min, regardless of its position in the cell cycle. Ki67 has been shown to be involved in ribosomal biogenesis, heterochromatin maintenance, and mitotic chromosome separation (2).

Detection of Ki67 by immunostaining is commonly used as a proliferation marker in solid tumors, as well as certain hematological malignancies (3-5). The Ki67 index, which reports on positive Ki67 stained tumor cell nuclei, has been extensively studied as a prognostic biomarker in cancers such as breast cancer and cervical cancer.

References

1. Gerdes J, Schwab U, Lemke H, Stein H. (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 31:13-20. PMID: 6339421

2. Starborg M, Gell K, Brundell E and Hoog C. (1996) The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci. 109:143-153. 1996

3. Karamitopoulou E, Perentes E, Tolnay M, Probst A. (1998) Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol. 29(2):140-5. PMID: 9490273

4. Geyer FC, Rodrigues DN, Weigelt B and Reis-Filho JS. (2012) Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 19(1):39-53. PMID: 22156833

5. Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R; PALMS Study Group. (2013) Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 105(20):1550-7. PMID: 24096620

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 3 confirmed species: Human, Mouse, Zebrafish.

We have publications tested in 3 applications: IF/IHC, IHC-Fr, IHC-P.

Showing Publications 1 - 10 of 17. Show All 17 Publications. Collapse Publications.

Publications using NB110-90592	Applications	Species
Lin P, Lourenco C, Cruickshank J et al. Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality Cancer research 2023-11-21 [PMID: 37987734] (IHC-P, Mouse)	IHC-P	Mouse
Ahmadipour M, Taniguchi D, Duchesneau P Et al. Use of high-rate ventilation results in enhanced recellularization of bio-engineered lung scaffolds Tissue engineering. Part C, Methods 2021-11-30 [PMID: 34847779]
Rehman SK, Haynes J, Collignon E, et al. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy Cell 2021-01-07 [PMID: 33417860] (IF/IHC, Human)	IF/IHC	Human
Mealiea D, Boudreau E, De Silva N et al. Modeling oncolytic virus dynamics in the tumor microenvironment using zebrafish Cancer Gene Ther. 2020-07-10 [PMID: 32647136] (IHC-P, Zebrafish)	IHC-P	Zebrafish
Lourenco C, Kalkat M, Houlahan KE et al. Modelling the MYC-driven normal-to-tumour switch in breast cancer Dis Model Mech 2019-07-26 [PMID: 31350286] (IHC-P, Human)	IHC-P	Human
Lima-Fernandes, E;Murison, A;da Silva Medina, T;Wang, Y;Ma, A;Leung, C;Luciani, GM;Haynes, J;Pollett, A;Zeller, C;Duan, S;Kreso, A;Barsyte-Lovejoy, D;Wouters, BG;Jin, J;Carvalho, DD;Lupien, M;Arrowsmith, CH;O'Brien, CA; Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells Nat Commun 2019-03-29 [PMID: 30926792] (IF/IHC, Human)	IF/IHC	Human
Kalkat M, Resetca D, Lourenco C et al. MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis. Mol. Cell. 2018-10-30 [PMID: 30415952] (IF/IHC, Human)	IF/IHC	Human
Kato T, Jin CS, Lee D et al. Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma. Int. J. Oncol. 2018-11-01 [PMID: 30226590] (IF/IHC, Human)	IF/IHC	Human
Kato T, Lee D, Huang H et al. Personalized siRNA-nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer. Mol. Cancer Res. 2017-10-09 [PMID: 28993508] (Human)		Human
Ernsting MJ, Hoang B, Lohse I et al. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. J Control Release. 2015-03-21 [PMID: 25804872] (IF/IHC, Mouse)	IF/IHC	Mouse
Tan Q, Joshua AM, Saggar JK et al. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy Br. J. Cancer. 2015-03-03 [PMID: 25647012] (IHC-Fr, Human) Details: Ki-67/MKI67 antibody used for IHC-Fr on PC3 xenograft cryosections obtained from mice that were subjected or not to 24 hours of treatments with pantoprazole/PTP, docetaxel/DOC or PTP+DOC (docetaxel-treatment after pretreatment with pantoprazole). Ki67 was used as a marker of cell proliferation and the latter was found to be reduced in antimals treated with a combination of pantoprazole and docetaxel compared to the ones treated with either drugs alone (Figure 2D).	IHC-Fr	Human
Zhao JJ, Lin J, Zhu D et al. miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/betta-Catenin/BCL9 Pathway. Cancer Res. 2014-03-15 [PMID: 24599134] (IHC-P, Human)	IHC-P	Human
Clarissa A Cassol, Daniel Winer, Wei Liu et al. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Modern Pathology 2014-01-01 [PMID: 24390213] (IHC-P, Human)	IHC-P	Human
Ciucurel E, Sefton MV. Using Del-1 to Tip the Angiogenic Balance in Endothelial Cells in Modular Constructs. Tissue Eng Part A. 2013-10-20 [PMID: 24138448] (IHC-P, Human)	IHC-P	Human
Wei W, Liu W, Cassol C et al. The Breast Cancer Susceptibility Gene FGFR2 Serves as a Scaffold for Regulation of NF-kB Signaling Mol Cell Biol 2012-09-17 [PMID: 22988296] (IF/IHC, Mouse, Human)	IF/IHC	Mouse, Human
Serra S, Zheng L, Hassan M et al. The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy Cancer Res 2012-11-15 [PMID: 22986737] (IF/IHC, Mouse)	IF/IHC	Mouse
Fung AS, Jonkman J, Tannock IF. Quantitative immunohistochemistry for evaluating the distribution of ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with Paclitaxel. Neoplasia;14(4):324-34. 2012-04-01 [PMID: 22577347] (IF/IHC, Mouse)	IF/IHC	Mouse
Show All 17 Publications. Collapse Publications.

Images	Ratings	Applications	Species	Date	Details
	4 reviewed by: Kelsey Stockbridge	IF	Mouse	12/22/2010	View Summary Application Immunofluorescence Sample Tested mouse small intestinal epithelial cell line Species Mouse

Array NB110-90592

• Ki67/MKI67 Antibodies
• Ki67/MKI67 Proteins
• Ki67/MKI67 ELISA